The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Details

Ressource 1Download: document.pdf (1803.04 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_A62033B5071E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Journal
Cardiovascular Diabetology
Author(s)
Fruchart J.C., Santos R.D., Aguilar-Salinas C., Aikawa M., Al Rasadi K., Amarenco P., Barter P.J., Ceska R., Corsini A., Després J.P., Duriez P., Eckel R.H., Ezhov M.V., Farnier M., Ginsberg H.N., Hermans M.P., Ishibashi S., Karpe F., Kodama T., Koenig W., Krempf M., Lim S., Lorenzatti A.J., McPherson R., Nuñez-Cortes J.M., Nordestgaard B.G., Ogawa H., Packard C.J., Plutzky J., Ponte-Negretti C.I., Pradhan A., Ray K.K., Reiner Ž., Ridker P.M., Ruscica M., Sadikot S., Shimano H., Sritara P., Stock J.K., Su T.C., Susekov A.V., Tartar A., Taskinen M.R., Tenenbaum A., Tokgözoğlu L.S., Tomlinson B., Tybjærg-Hansen A., Valensi P., Vrablík M., Wahli W., Watts G.F., Yamashita S., Yokote K., Zambon A., Libby P.
ISSN
1475-2840 (Electronic)
ISSN-L
1475-2840
Publication state
Published
Issued date
04/06/2019
Peer-reviewed
Oui
Volume
18
Number
1
Pages
71
Language
english
Abstract
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
Keywords
Atherogenic dyslipidemia, Diabetes, Inflammation, PROMINENT, Pemafibrate (K-877), Remnant cholesterol, Residual cardiovascular risk, SPPARMalpha, Selective peroxisome proliferator-activated receptor alpha modulator, Triglycerides, Visceral obesity
Pubmed
Web of science
Open Access
Yes
Create date
20/06/2019 8:53
Last modification date
20/08/2019 15:11
Usage data